Create issue ticket

9,528 Possible Causes for Activating, Factor, Inhibitors, Platelet, [MoA]

  • Acquired Hemophilia

    Two independent factors (the use of a Rb regimen and platelet 1.5 10(11)/L) were significantly associated with TRS. Copyright 2013. Published by Elsevier B.V.[ncbi.nlm.nih.gov] The APTT was prolonged, at 140 s, and factor VIII inhibitor was 36 Bethesda U/ml.[ncbi.nlm.nih.gov] We report on a 92-year-old male, administered two courses of 90 microg kg(-1) of recombinant activated factor VII (rFVIIa) due to failure of human factor VIII (FVIII) therapy[ncbi.nlm.nih.gov] We started combination treatment with bypassing agent, activated prothrombin complex and immunosuppressants immediately and the results were successful.[ncbi.nlm.nih.gov] At induction of anesthesia, he received tranexamic acid, prothrombin complex concentrate, and platelets.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Bleeding Diathesis

    Additionally, FCA is able to identify discrete platelet activation defects.[ncbi.nlm.nih.gov] […] the resultant protease/protease inhibitor complexes.[ncbi.nlm.nih.gov] These discrepancies between Factor V activities and antigen concentration do not appear to be due to an unstable Factor V molecule or to the presence of a Factor V or Factor[ncbi.nlm.nih.gov] INTRODUCTION: Factor VIII (FVIII) treatment for hemophilia A has difficulties in correcting bleeding diathesis in the presence of inhibitors.[ncbi.nlm.nih.gov] Xa coagulant activity.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Thrombotic Thrombocytopenic Purpura

    BACKGROUND: Platelet microparticles (PMPs) have a procoagulant activity about 50-100 times greater than active platelets due to high expression of negatively charged phospholipids[ncbi.nlm.nih.gov] Functional inhibitor assays were performed using internally developed mixing protocols.[ncbi.nlm.nih.gov] Most cases in adults are caused by acquired autoantibodies that inhibit ADAMTS13, a metalloprotease that cleaves von Willebrand factor within nascent platelet-rich thrombi[ncbi.nlm.nih.gov] Willebrand factor.[dx.doi.org] Abstract BACKGROUND: In thrombotic thrombocytopenic purpura (TTP), platelet (PLT) transfusion is contraindicated unless a life-threatening hemorrhage occurs.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Factor V Deficiency

    Recently, we have shown that three patients with undetectable plasma FV and mild bleeding symptoms had sufficient residual platelet FV to support thrombin generation in platelet-rich[ncbi.nlm.nih.gov] KEYWORDS: factor V inhibitor; fresh frozen plasma; platelet concentrate; recombinant activated factor VII; thrombin generation assay[ncbi.nlm.nih.gov] activate factor X and prothrombin on the surface of activated platelets.[ncbi.nlm.nih.gov] BACKGROUND AND OBJECTIVES: Factor V HR2 possesses decreased co-factor activity to activated protein C and an increased ratio of factor V1 to factor V2.[ncbi.nlm.nih.gov] Activated recombinant coagulation factor VII (rFVIIa) was used as an alternative haemostatic agent to FFP.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Acquired Von Willebrand Syndrome

    Platelet dysfunction and acquired von Willebrand syndrome (AVWS) may contribute to bleeding tendencies.[ncbi.nlm.nih.gov] This unique inhibitor offers a molecular probe to examine the von Willebrand factor: platelet interaction.[ncbi.nlm.nih.gov] Abstract A case of acquired von Willebrand's syndrome (vWs) is described which appeared to be due to antibodies directed against factor VIII clotting activity (FVIIIC), factor[ncbi.nlm.nih.gov] At diagnosis, VWF activity (VWF:Act), antigen (VWF:Ag), multimers, and factor VIII coagulant activity were virtually absent.[ncbi.nlm.nih.gov] Further testing revealed factor VIII (FVIII) activity of 16%, factor IX (FIX) activity of 74%, von Willebrand factor (VWF) activity of 12%, VWF antigen activity of 31%, and[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Eptifibatide

    Human platelets treated 'in vitro' with Abci or Epti exhibit changes in the phospholipid ratio in the platelet membrane. The ratio of PS decreases and PC rises.[ncbi.nlm.nih.gov] CONCLUSIONS: It is important to monitor platelet counts closely after initiation of GPIIb/IIIa inhibitor therapy, not only for abciximab, but also for small molecule inhibitors[ncbi.nlm.nih.gov] Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial demonstrated safety of recombinant tissue-type plasminogen activator[ncbi.nlm.nih.gov] List the class for eptifibatide/integrilin Glycoprotein IIb/IIIa inhibitor, platelet aggregation inhibitor List the MOA for eptifibatide/integrilin Prevents the aggregation[quizlet.com] Abstract Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its[ncbi.nlm.nih.gov]

  • Acquired Hemophilia A

    Two independent factors (the use of a Rb regimen and platelet 1.5 10(11)/L) were significantly associated with TRS. Copyright 2013. Published by Elsevier B.V.[ncbi.nlm.nih.gov] The APTT was prolonged, at 140 s, and factor VIII inhibitor was 36 Bethesda U/ml.[ncbi.nlm.nih.gov] The patient was successfully treated with activated recombinant human factor VII (rhFVIIa) and immunosuppression.[ncbi.nlm.nih.gov] At induction of anesthesia, he received tranexamic acid, prothrombin complex concentrate, and platelets.[ncbi.nlm.nih.gov] The presence of factor VIII inhibitor is confirmed, and the co-existence of two autoimmune diseases is discussed.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Acquired Thrombotic Thrombocytopenic Purpura

    Maximal increase of platelet adhesion was observed under 2,050 s(-1) .[ncbi.nlm.nih.gov] CONCLUSION: Findings from this cohort of aTTP patients demonstrated that inhibitor boosting often occurs in aTTP patients in Japan.[ncbi.nlm.nih.gov] Twenty plasma samples with non-concordant ADAMTS13 activity results, KEYWORDS: ADAMTS13 activity assay; TTP; autoantibodies; flow assay; von Willebrand factor[ncbi.nlm.nih.gov] […] agglutination in patients with thrombotic thrombocytopenic purpura (TTP) appears to be associated with excessive release from endothelial cells of unusually large von Willebrand factor[ncbi.nlm.nih.gov] In patients with both acute and remission samples available, VWF ristocetin co-factor activity (VWF:RCo) and collagen binding (VWF:CB) were also measured.[ncbi.nlm.nih.gov]

    Missing: [MoA]
  • Hemophilia A

    platelet P-selectin expression, a lower number of procoagulant, so-called 'coated' platelets, lower aggregation upon co-incubation with tissue factor, or reduced platelet[ncbi.nlm.nih.gov] RESULTS: A total of 109 male participants with hemophilia A with inhibitors were enrolled.[ncbi.nlm.nih.gov] Abstract This study investigated the disposition of coagulation factor VIII activity in 754 patients with moderate to severe hemophilia A following the administration of moroctocog[ncbi.nlm.nih.gov] Franchini M, Lippi G ; Acquired factor VIII inhibitors. Blood. 2008 Jul 15112(2):250-5. doi: 10.1182/blood-2008-03-143586. Epub 2008 May 7.[patient.info] The A2 subunit of factor VIIIa modulates the active site of factor IXa . J. Biol. Chem. 273 , 19049–19054 (1998). 17. Lapan, K.A. & Fay, P.J.[nature.com]

    Missing: [MoA]
  • Atypical Hemolytic Uremic Syndrome

    […] of platelets with purified CFH.[ncbi.nlm.nih.gov] Eculizumab, a terminal complement inhibitor approved for aHUS treatment, was reported to improve hematologic and renal parameters in 2 prior prospective phase 2 studies.[ncbi.nlm.nih.gov] […] as "cryptic activity of aHUS."[ncbi.nlm.nih.gov] She showed only one cardiovascular risk factor, hypercholesterolaemia.[doi.org] We tested the in vitro ability of eculizumab to inhibit complement activation in HELLP serum.[ncbi.nlm.nih.gov]

    Missing: [MoA]